DNLI
Denali Therapeutics Inc. Common Stock
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Best Biotech Stocks 2026 →
Denali Therapeutics (DNLI) Stock: Buy, Sell, or Hold?
$18.89
-0.84 (-4.26%)
âŧ
5d:
-4.21%
30d:
+5.71%
90d:
-22.58%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (76%)
Quality Score
52/100
Position
FAIR
30-Day Fair Range
$18.36 â $19.83
Position: FAIR
Forward P/E & Valuation
-8.5x
Next 12M consensus est.
Wall Street Target
$36.19
+91.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$18.32 / $22.19
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: DNLI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When DNLI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: DNLI is currently trading at $18.89, which is considered fair relative to its 30-day fair value range of $18.36 to $19.83.
Technical Outlook: Technically, DNLI is in a strong downtrend. Immediate support is located at $18.32, while resistance sits at $22.19. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $36.19 (+91.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DNLI is in a strong downtrend. Immediate support is located at $18.32, while resistance sits at $22.19. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $36.19 (+91.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$18.36 -
$19.83
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.8%
Trading Range & Key Levels
30-Day Trading Range
$18.36 -
$19.83
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$2.16
(11.4%)
Support Level
$18.32
Resistance Level
$22.19
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (46/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 91.6% below Wall St target ($36.19)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-8.46
Wall Street Target
$36.19
(+91.6%)
Revenue Growth (YoY)
-100.0%
Share DNLI Analysis
Share this live DNLI analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (DNLI)
Bullish
3 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
2 msgs
24h retail stream
Last Tracked
Nov 4, 2026
Daily AI digest
AI Retail Discussion Summary:
Denali Therapeutics reported strong Q3 earnings, with AVLAYAH sales exceeding expectations and a permanent J-code now in effect. Shares rose 9.8% in after-hours trading.
Key Retail Themes:
Earnings beat and revenue surpassing estimates
Success of AVLAYAH, the first FDA-approved medicine for Hunter syndrome
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 13, 2026 4:15 AM ET
Data refreshes hourly during market hours. Next update: 5:15 AM
Data refreshes hourly during market hours. Next update: 5:15 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNLI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
28 analysts |
$978 | 32 SELL |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 52 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$17 | 37 SELL |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 42 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$296 | 24 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive DNLI Research Pages
